ZyVersa Therapeutics, Inc. (NASDAQ:ZVSA – Get Free Report) shares traded up 65.4% during trading on Friday . The company traded as high as $0.2670 and last traded at $0.2652. 1,507,772 shares traded hands during trading, an increase of 349% from the average session volume of 336,132 shares. The stock had previously closed at $0.1603.
ZyVersa Therapeutics Trading Up 65.4%
The stock has a market capitalization of $2.10 million, a P/E ratio of -0.20 and a beta of 0.81. The stock has a 50 day moving average of $0.14 and a 200-day moving average of $0.21.
ZyVersa Therapeutics Company Profile
ZyVersa Therapeutics, Inc, a clinical stage biopharmaceutical company, develops and commercializes products for the treatment of renal and inflammatory diseases. The company develops drug development platforms, including Cholesterol Efflux Mediator VAR 200, an injectable drug, which is in Phase 2a clinical trial to the treatment of renal indications, such as focal segmental glomerulosclerosis, alport syndrome, and diabetic kidney diseases; and Inflammasome ASC Inhibitor IC 100, a humanized monoclonal antibody that is in preclinical stage for treatment of inflammatory diseases comprising acute respiratory syndrome, multiple sclerosis, IgA neuropathy, pancreatic cancer, Parkinson's and Huntington's disease, atherosclerosis, Alzheimer's disease, and obesity.
Featured Articles
- Five stocks we like better than ZyVersa Therapeutics
- Elon Taking SpaceX Public! $100 Pre-IPO Opportunity!
- A U.S. “birthright” claim worth trillions – activated quietly
- Ticker Revealed: Pre-IPO Access to “Next Elon Musk” Company
- First Time Since 2007: All Warnings Active
- How the Rich Retire
Receive News & Ratings for ZyVersa Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for ZyVersa Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.
